ImmunoGen, Inc.
Apr 26, 2013

ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) antibody-drug conjugate (ADC) technology, today reported financial results for the three-month period ended March 31, 2013 — the third quarter of the Company's 2013 fiscal year — and provided an update on the Company.

"Based on published clinical findings and patient anecdotes, we believe Kadcyla will make a notable difference for many patients and become a highly successful product," commented Daniel Junius, President and CEO. "The first Kadcyla sales information reported by Roche in its quarterly update support that the product launch is off to a good start. As noted previously, we will be reporting our royalty revenue from Kadcyla one quarter in arrears and thus it will begin to be reported in our next quarter."

Mr. Junius continued, "While we are highly excited about Kadcyla, we believe even greater value for our shareholders will come from our wholly owned compounds. Patient enrollment is going well in our IMGN901, IMGN853, and IMGN529 clinical trials, and we are on track to advance our next compound, IMGN289, into the clinic later this year. Each of these compounds is highly differentiated and has the potential to become an important therapy for cancers that need better treatment options."

Product Pipeline Update

Financial Results and Guidance

ImmunoGen reported a net loss of $1.4 million, or $0.02 per basic and diluted share, for the quarter ending March 31, 2013 (3Q FY2013), as compared to a net loss of $18.7 million, or $0.24 per basic and diluted share, for the same quarter of the last year (3Q FY2012).

Revenues for 3Q FY2013 were $25.0 million, compared to $3.3 million for 3Q FY2012. Current quarter revenues include the $10.5 million milestone payment from Roche earned with the approval of Kadcyla in the US, and $11.1 million of amortization of upfront license fees received from Novartis. Revenues in 3Q FY2013 also comprise $2.3 million of research and development support fees and $0.7 million of clinical material reimbursement, compared to $1.3 million and $0.9 million, respectively, for the same quarter last year.

Operating expenses for 3Q FY2013 were $26.3 million, compared to $22.0 million in the same quarter last year. Operating expenses in 3Q FY2013 include research and development expenses of $21.3 million, compared to $16.9 million in 3Q FY2012. This change is primarily due to increased spending by the Company to aggressively advance its wholly owned product candidates, and includes increased costs for third-party production of antibody for use in clinical materials and also increased personnel expenses. Additionally, operating expenses include general and administrative expenses of $5.0 million in both 3Q FY2013 and 3Q FY2012.

ImmunoGen had approximately $206.1 million in cash and cash equivalents as of March 31, 2013 and no debt. Cash used in operations was $48.7 million in the first nine months of FY2013, compared with $18.1 million in the same period in FY2012. Capital expenditures were $2.4 million and $1.8 million for the first nine months of FY2013 and FY2012, respectively.

Financial Guidance

ImmunoGen now expects its net loss for its fiscal year ending June 30, 2013 to be between $76 million to $80 million, its net cash used in operations to be between $65 million to $69 million, and its capital expenditures to be between $4 million to $5 million. Cash and cash equivalents at June 30, 2013 are anticipated to be between $186 million to $190 million.

This compares with previous guidance, issued in January 2013, of a projected net loss between $70 million to $74 million, net cash used in operations of between $78 million to $82 million, comparable capital expenditures, and ending the fiscal year on June 30, 2013 with cash and cash equivalents between $172 million to $176 million.

"We expect our net cash used in operations to be lower than previously projected — driving our ending cash balance higher — primarily because of lower than expected operating expenses and working capital needs," commented Gregory Perry, Executive Vice President and CFO. "Also, we now anticipate that some licenses that we had expected to be taken in this fiscal year may be taken in our 2014 fiscal year, shifting the recognition of the associated deferred revenue into our next fiscal year. As a result, we have increased our projected net loss in our revised guidance."

Conference Call Information

ImmunoGen is holding a conference call today at 8:00 am ET to discuss the quarterly results. To access the live call by phone, dial 913-312-0843. Passcode is 4566767. The call also may be accessed through the Investor Information section of the Company's website, Following the live webcast, a replay of the call will be available at the same location through May 10, 2013.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's TAP technology uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells. Ten TAP compounds are now in the clinic, of which three are wholly owned by the Company. The most advanced compound using ImmunoGen's TAP technology, Kadcyla, has been approved for marketing in the US and is undergoing regulatory review in Europe and Japan; it is being commercialized in the US by Genentech, a member of the Roche Group. More information about ImmunoGen can be found at

Herceptin® is a registered trademark of Genentech. Kadcyla™ is a trademark of Genentech.

This press release includes forward-looking statements based on management's current expectations. These statements include, but are not limited to, ImmunoGen's expectations related to: the Company's net loss, cash used in operations and capital expenditures in its 2013 fiscal year; its cash and cash equivalents as of June 30, 2013; the occurrence, timing and outcome of potential pre-clinical, clinical and regulatory events related to the Company's and its collaboration partners' product programs; and the presentation of preclinical and clinical data on the Company's and collaboration partners' product candidates. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Various factors could cause ImmunoGen's actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the timing and outcome of ImmunoGen's and the Company's collaboration partners' research and clinical development processes; the difficulties inherent in the development of novel pharmaceuticals, including uncertainties as to the timing, expense and results of preclinical studies, clinical trials and regulatory processes; ImmunoGen's ability to financially support its product programs; ImmunoGen's dependence on collaborative partners; industry merger and acquisition activity; and other factors more fully described in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2012 and other reports filed with the Securities and Exchange Commission.

(in thousands, except per share amounts)
March 31, June 30,


Cash and cash equivalents $ 206,103 $ 160,938
Other assets   22,579   19,370
Total assets $ 228,682 $ 180,308
Current liabilities $ 16,814 $ 16,254
Long-term portion of deferred revenue and other long-term liabilities 72,866 80,164
Shareholders' equity   139,002   83,890
Total liabilities and shareholders' equity $ 228,682 $ 180,308
        Three Months Ended     Nine Months Ended
March 31, March 31,
2013   2012 2013   2012
License and milestone fees $ 22,010 $ 999 $ 23,372 $ 8,211
Research and development support 2,257 1,320 5,670 $ 3,333
Clinical materials reimbursement   734     933     2,662     1,861  
Total revenues   25,001     3,252     31,704     13,405  
Research and development 21,318 16,933 66,674 49,653
General and administrative   4,995     5,021     16,098     14,696  
Total operating expenses   26,313     21,954     82,772     64,349  
Loss from operations (1,312 ) (18,702 ) (51,068 ) (50,944 )
Other (expense) income, net   (39 )   33     132     39  
Net loss $ (1,351 ) $ (18,669 ) $ (50,936 ) $ (50,905 )
Net loss per common share, basic and diluted $ (0.02 ) $ (0.24 ) $ (0.61 ) $ (0.66 )
Weighted average common shares outstanding, basic and diluted 84,279     76,961     83,923     76,615  

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
For Media:
The Yates Network
Barbara Yates, 781-258-6153

Source: ImmunoGen, Inc.

News Provided by Acquire Media